About FibroGenesis

FibroGenesis, is a regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts.

FibroGenesis is undertaking an accelerated preclinical program to find a cure for COVID-19 Acute Respiratory Distress Syndrome (ARDS) using its advanced fibroblast cell therapy.

Multi-Pronged Attack on COVID-19:

FibroMune™ and PneumoBlast™

Current Projects

We are developing two products for treatment of COVID-19.  The first, FibroMune™, is comprised of conditioned media from activated fibroblasts, which induces interferon beta production when administered.  FibroMune™ is being developed to activate innate immunity in order to prevent virus propagation.  PneumoBlast™ is comprised of proprietary “universal donor” fibroblasts for the treatment of acute respiratory distress syndrome (ARDS), which is the main cause of COVID-19 mortality. 

Recent News

November 10, 2020

FibroGenesis Reaches Milestone to File Its 250th Patent  

Read More


October 8, 2020

FibroGenesis Named #2 Most Innovative Company of 2020  

Read More


October 1, 2020

FibroGenesis Announces Collaboration Agreement with Brazilian Biotech R4D  Read More

September 28, 2020

FibroGenesis Announces Manufacturing Agreement  Read More

August 12, 2020

FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting  Read More


July 21, 2020

FibroGenesis Reduces COVID-19 Lung Scarring in Animal Model  Read More


July 1, 2020

FibroGenesis Identifies Mechanism Responsible for Blocking COVID-19 Lung Inflammation  Read More

Intellectual Property

Currently, FibroGenesis holds 240 U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Colitis, Cancer, Diabetes, Liver Failure and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.

Twitter Updates

Fibroblast cells.jpg

 Copyright © 2020 FibroGenesis. All rights reserved.